Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease
Ho Cheol Kim, Jung Su Lee, Sang Hyung Kim, Hoon Sub So, Chang Yoon Woo, Jae Lyun Lee
Cancer Res Treat. 2013;45(4):349-353.   Published online 2013 Dec 31     DOI: https://doi.org/10.4143/crt.2013.45.4.349
Citations to this article as recorded by Crossref logo

Von Hippel-Lindau Disease: Current Challenges and Future Prospects

Sven Gläsker, Evelynn Vergauwen, Christian A Koch, Alexander Kutikov, Alexander O Vortmeyer
OncoTargets and Therapy.2020; Volume 13: 5669.     CrossRef
The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma
Song Peng, Jun Zhang, Xintao Tan, Yiqiang Huang, Jing Xu, Natalie Silk, Dianzheng Zhang, Qiuli Liu, Jun Jiang
Frontiers in Endocrinology.2020;[Epub]     CrossRef
Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights
Maria I. Carlo, A. Ari Hakimi, Grant D. Stewart, Gennady Bratslavsky, James Brugarolas, Ying-Bei Chen, W. Marston Linehan, Eamonn R. Maher, Maria J. Merino, Kenneth Offit, Victor E. Reuter, Brian Shuch, Jonathan A. Coleman
European Urology.2019; 76(6): 754.     CrossRef
The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel–Lindau Disease: A Retrospective Study of 32 Patients
Kaifang Ma, Baoan Hong, Jingcheng Zhou, Yanqing Gong, Jiangyi Wang, Shengjie Liu, Xiang Peng, Bowen Zhou, Jiufeng Zhang, Haibiao Xie, Kenan Zhang, Lei Li, Desheng Cai, Zixin Wang, Lin Cai, Kan Gong
Frontiers in Oncology.2019;[Epub]     CrossRef
A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease
Gang Yuan, Qiuli Liu, Dali Tong, Gaolei Liu, Yuting Yi, Jun Zhang, Yao Zhang, Lin-ang Wang, Luofu Wang, Rongrong Chen, Yanfang Guan, Xin Yi, Weihua Lan, Jun Jiang
Cancer Biology & Therapy.2018; 19(9): 766.     CrossRef
Genetic Predisposition to Renal Cell Carcinoma: Implications for Counseling, Testing, Screening, and Management
Brian Shuch, Jin Zhang
Journal of Clinical Oncology.2018; 36(36): 3560.     CrossRef
A Case of von Hippel–Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas
Su Jin Heo, Choong-kun Lee, Kyu Yeon Hahn, Gyuri Kim, Hyuk Hur, Sung Hoon Choi, Kyung Seok Han, Arthur Cho, Minkyu Jung
Cancer Research and Treatment.2016; 48(1): 409.     CrossRef
Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease
Akihiro Kobayashi, Masanobu Takahashi, Hiroo Imai, Shoko Akiyama, Shunsuke Sugiyama, Keigo Komine, Ken Saijo, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Naomi Sato, Fumiyoshi Fujishima, Taro Shuin, Hideki Shimodaira, Chikashi Ishioka
Internal Medicine.2016; 55(6): 629.     CrossRef
Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group
Stéphane Oudard, Reza Elaidi, Mara Brizard, Céline Le Rest, Valérie Caillet, Sophie Deveaux, Gérard Benoit, Jean-Michel Corréas, Farida Benoudiba, Philippe David, Alain Gaudric, Pascal Hammel, Dominique Joly, Marc Olivier Timsit, Arnaud Méjean, Stéphane R
Oncotarget.2016; 7(51): 85306.     CrossRef
Pharmacogenomic biomarkers for personalized cancer treatment
C. Rodríguez-Antona, M. Taron
Journal of Internal Medicine.2015; 277(2): 201.     CrossRef
Pharmacological HIF2α inhibition improves VHL disease–associated phenotypes in zebrafish model
Ana Martins Metelo, Haley R. Noonan, Xiang Li, Youngnam Jin, Rania Baker, Lee Kamentsky, Yiyun Zhang, Ellen van Rooijen, Jordan Shin, Anne E. Carpenter, Jing-Ruey Yeh, Randall T. Peterson, Othon Iliopoulos
Journal of Clinical Investigation.2015; 125(5): 1987.     CrossRef
Molecular and immunologic markers of kidney cancer—potential applications in predictive, preventive and personalized medicine
Amanda Mickley, Olga Kovaleva, Julia Kzhyshkowska, Alexei Gratchev
EPMA Journal.2015;[Epub]     CrossRef